S&P 500   4,205.52 (+0.00%)
DOW   33,042.78 (-0.15%)
QQQ   350.43 (+0.58%)
AAPL   177.64 (+1.26%)
MSFT   332.07 (-0.25%)
META   262.76 (+0.27%)
GOOGL   123.82 (-0.63%)
AMZN   121.83 (+1.43%)
TSLA   200.45 (+3.77%)
NVDA   400.09 (+2.73%)
NIO   7.46 (-3.12%)
BABA   78.71 (-2.79%)
AMD   125.46 (-1.24%)
T   15.67 (+1.10%)
F   12.62 (+4.38%)
MU   72.08 (-2.50%)
CGC   0.85 (-3.10%)
GE   102.37 (-0.36%)
DIS   87.74 (-0.62%)
AMC   4.64 (+0.00%)
PFE   37.06 (-1.44%)
PYPL   62.16 (+3.22%)
NFLX   392.72 (+3.65%)
S&P 500   4,205.52 (+0.00%)
DOW   33,042.78 (-0.15%)
QQQ   350.43 (+0.58%)
AAPL   177.64 (+1.26%)
MSFT   332.07 (-0.25%)
META   262.76 (+0.27%)
GOOGL   123.82 (-0.63%)
AMZN   121.83 (+1.43%)
TSLA   200.45 (+3.77%)
NVDA   400.09 (+2.73%)
NIO   7.46 (-3.12%)
BABA   78.71 (-2.79%)
AMD   125.46 (-1.24%)
T   15.67 (+1.10%)
F   12.62 (+4.38%)
MU   72.08 (-2.50%)
CGC   0.85 (-3.10%)
GE   102.37 (-0.36%)
DIS   87.74 (-0.62%)
AMC   4.64 (+0.00%)
PFE   37.06 (-1.44%)
PYPL   62.16 (+3.22%)
NFLX   392.72 (+3.65%)
S&P 500   4,205.52 (+0.00%)
DOW   33,042.78 (-0.15%)
QQQ   350.43 (+0.58%)
AAPL   177.64 (+1.26%)
MSFT   332.07 (-0.25%)
META   262.76 (+0.27%)
GOOGL   123.82 (-0.63%)
AMZN   121.83 (+1.43%)
TSLA   200.45 (+3.77%)
NVDA   400.09 (+2.73%)
NIO   7.46 (-3.12%)
BABA   78.71 (-2.79%)
AMD   125.46 (-1.24%)
T   15.67 (+1.10%)
F   12.62 (+4.38%)
MU   72.08 (-2.50%)
CGC   0.85 (-3.10%)
GE   102.37 (-0.36%)
DIS   87.74 (-0.62%)
AMC   4.64 (+0.00%)
PFE   37.06 (-1.44%)
PYPL   62.16 (+3.22%)
NFLX   392.72 (+3.65%)
S&P 500   4,205.52 (+0.00%)
DOW   33,042.78 (-0.15%)
QQQ   350.43 (+0.58%)
AAPL   177.64 (+1.26%)
MSFT   332.07 (-0.25%)
META   262.76 (+0.27%)
GOOGL   123.82 (-0.63%)
AMZN   121.83 (+1.43%)
TSLA   200.45 (+3.77%)
NVDA   400.09 (+2.73%)
NIO   7.46 (-3.12%)
BABA   78.71 (-2.79%)
AMD   125.46 (-1.24%)
T   15.67 (+1.10%)
F   12.62 (+4.38%)
MU   72.08 (-2.50%)
CGC   0.85 (-3.10%)
GE   102.37 (-0.36%)
DIS   87.74 (-0.62%)
AMC   4.64 (+0.00%)
PFE   37.06 (-1.44%)
PYPL   62.16 (+3.22%)
NFLX   392.72 (+3.65%)
TSE:IVQ

Invesque (IVQ) Competitors

C$1.00
-0.03 (-2.91%)
(As of 10:57 AM ET)
Compare
Today's Range
C$1.00
C$1.03
50-Day Range
C$1.00
C$1.22
52-Week Range
C$1.00
C$1.76
Volume
4,500 shs
Average Volume
11,948 shs
Market Capitalization
C$56.14 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A

IVQ vs. PMN, PDP, WMD, APS, IOM, CRDL, MDNA, MBX, HEXO, and DOC

Should you be buying Invesque stock or one of its competitors? The main competitors of Invesque include ProMIS Neurosciences (PMN), Pediapharm (PDP), WeedMD (WMD), Aptose Biosciences (APS), Assure (IOM), Cardiol Therapeutics (CRDL), Medicenna Therapeutics (MDNA), Microbix Biosystems (MBX), HEXO (HEXO), and CloudMD Software & Services (DOC). These companies are all part of the "medical" sector.

Invesque vs.

ProMIS Neurosciences (TSE:PMN) and Invesque (TSE:IVQ) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their analyst recommendations, earnings, dividends, institutional ownership, risk, profitability, valuation, community ranking and media sentiment.

2.2% of ProMIS Neurosciences shares are held by institutional investors. Comparatively, 27.1% of Invesque shares are held by institutional investors. 18.5% of ProMIS Neurosciences shares are held by company insiders. Comparatively, 31.0% of Invesque shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

ProMIS Neurosciences has a net margin of 0.00% compared to Invesque's net margin of -32.66%. Invesque's return on equity of -23.17% beat ProMIS Neurosciences' return on equity.

Company Net Margins Return on Equity Return on Assets
ProMIS Neurosciences N/A -837.71% -168.33%
Invesque -32.66% -23.17% 2.07%

ProMIS Neurosciences received 180 more outperform votes than Invesque when rated by MarketBeat users. Likewise, 70.86% of users gave ProMIS Neurosciences an outperform vote while only 60.71% of users gave Invesque an outperform vote.

CompanyUnderperformOutperform
ProMIS NeurosciencesOutperform Votes
197
70.86%
Underperform Votes
81
29.14%
InvesqueOutperform Votes
17
60.71%
Underperform Votes
11
39.29%

ProMIS Neurosciences has higher earnings, but lower revenue than Invesque. ProMIS Neurosciences is trading at a lower price-to-earnings ratio than Invesque, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
ProMIS NeurosciencesC$7.56 thousand7,833.02-C$20.93 million-C$3.70-1.86
InvesqueC$207.43 million0.27-C$58.69 million-C$0.94-1.06

In the previous week, Invesque had 3 more articles in the media than ProMIS Neurosciences. MarketBeat recorded 3 mentions for Invesque and 0 mentions for ProMIS Neurosciences. ProMIS Neurosciences' average media sentiment score of 0.00 beat Invesque's score of -0.13 indicating that ProMIS Neurosciences is being referred to more favorably in the media.

Company Overall Sentiment
ProMIS Neurosciences Neutral
Invesque Neutral

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
ProMIS Neurosciences
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
N/A
Invesque
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
N/A

ProMIS Neurosciences has a beta of 1.15, meaning that its stock price is 15% more volatile than the S&P 500. Comparatively, Invesque has a beta of 0.98, meaning that its stock price is 2% less volatile than the S&P 500.

Summary

Invesque beats ProMIS Neurosciences on 8 of the 15 factors compared between the two stocks.


New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding IVQ and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of TSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

IVQ vs. The Competition

MetricInvesqueMedical Care Facilities IndustryMedical SectorTSE Exchange
Market CapC$56.14MC$531.12MC$4.47BC$4.12B
Dividend YieldN/A2.56%2.41%5.10%
P/E Ratio-1.06187.2597.7426.15
Price / Sales0.2738.063,613.351,139.24
Price / Cash2.607.4122.2378.78
Price / Book0.431.434.503.78
Net Income-C$58.69M-C$17.33MC$117.08MC$328.69M
7 Day Performance-12.28%-0.28%-2.96%-2.62%
1 Month Performance-16.67%-7.23%0.38%-4.44%
1 Year Performance-40.12%-28.90%18.35%4.51%

Invesque Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
PMN
ProMIS Neurosciences
0 of 5 stars
C$7.24
-3.2%
N/A+6,030.4%C$62.12MC$7,558.00-2.215
PDP
Pediapharm
0 of 5 stars
C$0.30
+1.7%
N/A+0.0%C$66.36MC$11.16M-4.11N/A
WMD
WeedMD
0 of 5 stars
C$0.28
-1.8%
N/A+0.0%C$67.82MC$27.53M-0.66212Gap Up
APS
Aptose Biosciences
0 of 5 stars
C$0.64
flat
C$5.00
+681.3%
-52.5%C$59.53MN/A-1.0831
IOM
Assure
0 of 5 stars
C$5.40
-7.7%
N/A+0.0%C$69.22MC$25.50M-16.3191Gap Down
High Trading Volume
CRDL
Cardiol Therapeutics
0 of 5 stars
C$0.91
+12.3%
C$1.00
+9.9%
-40.7%C$57.97MN/A-2.02N/AGap Up
MDNA
Medicenna Therapeutics
0 of 5 stars
C$0.80
-4.8%
C$5.33
+566.7%
-36.4%C$55.71MN/A-5.0013Gap Up
MBX
Microbix Biosystems
0 of 5 stars
C$0.40
-4.8%
N/A-29.8%C$54.69MC$16.72M34.00N/AGap Up
HEXO
HEXO
1.6346 of 5 stars
C$1.67
-12.6%
C$3.42
+105.0%
-67.5%C$73.48MC$148.08M-0.762,021News Coverage
DOC
CloudMD Software & Services
0 of 5 stars
C$0.18
-2.7%
C$0.25
+38.9%
-56.1%C$54.30MC$114.46M-0.3581Gap Down

Related Companies and Tools

This page (TSE:IVQ) was last updated on 5/30/2023 by MarketBeat.com Staff

My Account -